(Q48064023)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26876205%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26876205%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

main subject

hepatocellular carcinoma

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26876205%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

M-H Hung

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26876205%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Y-L Chen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26876205%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

C-T Shih

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26876205%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

H-C Yu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26876205%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

W-T Tai

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26876205%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

C-W Shiau

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26876205%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

K-F Chen

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26876205%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

language of work or name

English

0 references

publication date

15 February 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26876205%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26876205%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26876205%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

issue

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26876205%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

4891-4902

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26876205%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/onc.2016.21

8 March 2020

exact match

0 references

cites work

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Global cancer statistics, 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Protein kinases and phosphatases in the control of cell fate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Protein phosphatase 2A: a target for anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Okadaic acid: an additional non-phorbol-12-tetradecanoate-13-acetate-type tumor promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Involvement of PP2A in viral and cellular transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Identification of specific PP2A complexes involved in human cell transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

PP2A: unveiling a reluctant tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

CIP2A inhibits PP2A in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

I(2)(PP2A) regulates p53 and Akt correlatively and leads the neurons to abort apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Accumulation of the SET protein in HEK293T cells and mild oxidative stress: cell survival or death signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Up-regulation of I-2(PP2A)/SET gene expression in rat primary hepatomas and regenerating livers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Proteomics identified overexpression of SET oncogene product and possible therapeutic utility of protein phosphatase 2A in alveolar soft part sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2(PP2A)/SET

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Direct observation of individual endogenous protein complexes in situ by proximity ligation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Surface plasmon resonance spectroscopy for characterisation of membrane protein-ligand interactions and its potential for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Fingolimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

VZV encephalitis that developed in an immunized patient during fingolimod therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Relationship between the structure of SET/TAF-I /INHAT and its histone chaperone activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Specific association between the human DNA repair proteins XPA and ERCC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Effects of the tumour promoter okadaic acid on intracellular protein phosphorylation and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Purification and characterization of two potent heat-stable protein inhibitors of protein phosphatase 2A from bovine kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.21

Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms' tumor

31 March 2020

1 reference

12 December 2020

Expression of I2PP2A, an inhibitor of protein phosphatase 2A, induces c-Jun and AP-1 activity

1 reference

12 December 2020

PP2A-Mediated Anticancer Therapy

1 reference

12 December 2020

The Saccharomyces cerevisiae SPT8 gene encodes a very acidic protein that is functionally related to SPT3 and TATA-binding protein

1 reference

12 December 2020